- Home
- XERS vs NSSC Comparison
XERS vs NSSC Comparison
Compare XERS & NSSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | NSSC |
|---|---|---|
| Founded | 2005 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | XERS | NSSC |
|---|---|---|
| Price | $8.21 | $36.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $10.83 | ★ $48.17 |
| AVG Volume (30 Days) | ★ 2.0M | 278.9K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 1.33% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | 0.01 | ★ 0.70 |
| Revenue | $49,590,000.00 | ★ $181,621,000.00 |
| Revenue This Year | $34.37 | $13.63 |
| Revenue Next Year | $22.86 | $10.05 |
| P/E Ratio | $832.00 | ★ $51.06 |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $4.87 | $29.27 |
| 52 Week High | $10.08 | $47.61 |
Technical Indicators
Market Signals| Indicator | XERS | NSSC |
|---|---|---|
| Relative Strength Index (RSI) | 57.84 | 45.79 |
| Support Level | $8.00 | $34.58 |
| Resistance Level | $8.42 | $36.88 |
| Average True Range (ATR) | 0.34 | 1.05 |
| MACD | -0.09 | -0.04 |
| Stochastic Oscillator | 39.00 | 44.10 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About NSSC NAPCO Security Technologies Inc.
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.